Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nutriband Equity Warrant Exp 30th Sep 2026 NTRBW

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its... see more

Recent & Breaking News (NDAQ:NTRBW)

Nutriband Inc. Issued Full Patent from the Korean Intellectual Property Office for Its "Abuse and Misuse Deterrent Transdermal System" Application

Accesswire December 31, 2021

Nutriband Inc. Announces $1 Million Share Repurchase Authorization

Accesswire December 29, 2021

Nutriband Inc. Initiates Plans to Offer Topical Lotion Contract Manufacturing Services

Accesswire December 21, 2021

Nutriband Inc. Receives cGMP Certification for Manufacturing Subsidiary

Accesswire December 13, 2021

Nutriband Inc. to Ring NASDAQ Stock Market Opening Bell on December 3, 2021

Accesswire December 3, 2021

Nutriband Inc. Initiates Commercial Development of Lead Product AVERSA(TM) Fentanyl

Accesswire November 16, 2021

Nutriband Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Accesswire November 10, 2021

Nutriband Inc. Receives Additional $2,062,500 from Exercise of Warrants, Increasing Total Capital from Public Offering and Nasdaq Listing to Approx. $8.7M

Accesswire October 22, 2021

Nutriband Inc. Signs Exclusive Manufacturing Agreement for Diocheck(TM) Visual COVID-19 Antibody Indicator Patch

Accesswire October 12, 2021

WestPark Capital Announces Completion of a $6.6 Million Public Offering for Nutriband Inc. (NASDAQ: NTRB) and Up-listing to the NASDAQ Capital Market

Business Wire October 5, 2021

Nutriband Inc.'s AVERSA(R) technology receives Notice of Allowance from United States Patent and Trademark Office (USPTO)

Accesswire October 4, 2021

Nutriband Inc. Prices $6.6 million Public Offering and Announces Uplisting to the NASDAQ Capital Market

Accesswire October 1, 2021